MET and neoplasm: However, a negative result from ctDNA NGS for oncogenic driver mutations cannot exclude therapies and further investigation is required.18 Therefore, the CAP/IASLC/AMP considers liquid biopsy not as a replacement for tissue biopsy but as an alternative when there is insufficient tumor tissue specimens or in cases where tissue specimens are not feasible.18 It is important to highlight that this recommendation was published before the FDA approval for MET exon 14 target therapy and RET fusion target therapy.